An adeno-associated viral bacteriophage vector (AAVP) comprising a phage DNA having an expression cassette insertion, wherein the expression cassette has two adeno-associated virus inverted terminal repeats, wherein said AAVP comprises a reporter gene and a therapeutic gene, which AAVP is for use in the treatment and prophylaxis of a hyperproliferative disease, wherein the reporter gene is for evaluating in situ expression by detecting the reporter gene activity, wherein evaluating AAVP expression (a) comprises administering a detectable label that is selectively metabolized by a cell expressing an AAVP nucleic acid, wherein the label is selected from the group consisting of fluorodeoxyglucose; 2'-fluoro-2'deoxy-1-β-D-arabionofuranosyl-5-ethyl-uracil (FEAU); 5-[ 123 I]-2'-fluoro-5-iodo-1β-D-arabinofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodo-1β-D-arabinofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodo-1β-D-arabino-furanosyl-uracil, 5-[ 18 F]-2'-fluoro-5-fluoro-1-β-D-arabinofuranosyl-uracil; 2-[ 11 I]-and 5-([ 11 C]-methyl)-2'-fluoro-5-methyl-1-β-D-arabinofuranosyl-uracil; 2-[ 11 C]-2'-fluoro-5-ethyl-1-β-D-arabinofuranosyl-uracil; 5-([ 11 C]-ethyl)-2'-fluoro-5-ethyl-1-β-D-arabino-furanosyl-uracil; 5-(2-[ 18 F]-ethyl)-2'-fluoro-5-(2-fluoro-ethyl)-1-β-D-arabinofuranosyl-uracil, 5-[ 123 I]-2'-fluoro-5-iodovinyl-1-β-D-arabinofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodovinyl-1-β-D-arabinofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodovinyl-1-β-D-arabino-furanosyl-uracil; 5- [ 123 I]-2'-fluoro-5-iodo-1-β-D-ribofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodo-1-β-D-ribofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodo-1-β-D-ribofuranosyl-uracil; 5-[ 123 I]-2'-fluoro-5-iodovinyl-1-β-D-ribofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodovinyl-1-β-D-ribofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodovinyl-1-β-D-ribofuranosyl-uracil; and 9-4-[ 18 F]-fluoro-3-(hydroxymethyl)butyl]guanine; and (b) is conducted by non-invasive detection of the reporter or an activity of the reporter, wherein the reporter is a kinase that modifies the detectable label, and wherein the AAVP comprises a moiety that selectively targets a tissue or cell targeted for treatment. (a) comprises administering a detectable label that is selectively metabolized by a cell expressing an AAVP nucleic acid, wherein the label is selected from the group consisting of fluorodeoxyglucose; 2'-fluoro-2'deoxy-1-β-D-arabionofuranosyl-5-ethyl-uracil (FEAU); 5-[ 123 I]-2'-fluoro-5-iodo-1β-D-arabinofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodo-1β-D-arabinofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodo-1β-D-arabino-furanosyl-uracil, 5-[ 18 F]-2'-fluoro-5-fluoro-1-β-D-arabinofuranosyl-uracil; 2-[ 11 I]-and 5-([ 11 C]-methyl)-2'-fluoro-5-methyl-1-β-D-arabinofuranosyl-uracil; 2-[ 11 C]-2'-fluoro-5-ethyl-1-β-D-arabinofuranosyl-uracil; 5-([ 11 C]-ethyl)-2'-fluoro-5-ethyl-1-β-D-arabino-furanosyl-uracil; 5-(2-[ 18 F]-ethyl)-2'-fluoro-5-(2-fluoro-ethyl)-1-β-D-arabinofuranosyl-uracil, 5-[ 123 I]-2'-fluoro-5-iodovinyl-1-β-D-arabinofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodovinyl-1-β-D-arabinofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodovinyl-1-β-D-arabino-furanosyl-uracil; 5- [ 123 I]-2'-fluoro-5-iodo-1-β-D-ribofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodo-1-β-D-ribofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodo-1-β-D-ribofuranosyl-uracil; 5-[ 123 I]-2'-fluoro-5-iodovinyl-1-β-D-ribofuranosyl-uracil; 5-[ 124 I]-2'-fluoro-5-iodovinyl-1-β-D-ribofuranosyl-uracil; 5-[ 131 I]-2'-fluoro-5-iodovinyl-1-β-D-ribofuranosyl-uracil; and 9-4-[ 18 F]-fluoro-3-(hydroxymethyl)butyl]guanine; and (b) is conducted by non-invasive detection of the reporter or an activity of the reporter, wherein the reporter is a kinase that modifies the detectable label,